New Stocks to watch in Tech, Automotive, Biotech and Retail; (Nasdaq: $LCFY) (CSE: $BPAI.CN) (NASDAQ: $FLNC) (NASDAQ: $ZAPP) (NASDAQ: $ZCAR) (Nasdaq: $CRSP) (NYSE: $BDX) (TSX: $ATZ.TO)

New Stocks to watch in Tech, Automotive, Biotech and Retail; (Nasdaq: $LCFY) (CSE: $BPAI.CN) (NASDAQ: $FLNC) (NASDAQ: $ZAPP) (NASDAQ: $ZCAR) (Nasdaq: $CRSP) (NYSE: $BDX) (TSX: $ATZ.TO)

 

 

 

 

August 2, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Tech, Automotive, Biotech and Retail Sectors.

 

The newest automotive stocks are involved in ride-share and 2-wheel EV’s respectively.

 

The latest tech companies use AI for their SEO, Digitasl Marketing and Cleantech solutions, respectively, while the newest biotech companies provide gene therapies and medical technologies.

 

The latest retail company is a Canadian–based luxury brand clothing firm.

 

Read this in full at https://www.investorideas.com/news/2024/main/08021Stocks.asp

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Tech Directories:

Locafy (Nasdaq:LCFY) is a globally recognized software-as-a-service technology company specializing in local search engine marketing. Founded in 2009, Locafy's mission is to revolutionize the US$700 billion SEO sector. We help businesses and brands increase search engine relevance and prominence in a specific proximity using a fast, easy, and automated approach.

 

BrandPilot AI Inc. (CSE: BPAI) the new identity of Xemoto Media Ltd., is headquartered in Toronto, Canada, with a global presence that spans multiple industries. BrandPilot's mission is to help businesses achieve their marketing goals through innovative and data-driven solutions. Through its proprietary technology platform, Spectrum, BrandPilot leverages the power of AI to provide digital marketing and advertising solutions that empower businesses of all sizes to forge enduring connections with their customers.

 

Fluence Energy (NASDAQ:FLNC) is a global market leader in energy storage products and services, and optimization software for renewables and storage. With a presence in 47 markets globally, Fluence Energy, Inc. provides an ecosystem of offerings to drive the clean energy transition, including modular, scalable energy storage products, comprehensive service offerings, and AI-enabled optimization software for managing and optimizing renewables and storage from any provider. The Company is transforming the way we power our world by helping customers create more resilient and sustainable electric grids.

 

New Stocks Added to the Automotive Directories:

Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) and its operating subsidiaries are run by a team of experts from the mobility industry, on a mission to redefine the electric two-wheeler segment. Zapp's debut product, the i300, is an urban electric high-performance two-wheeler capable of traditional motorcycle levels of performance in a step-through format, combining ease of use with exhilaration and fun. The i300 is the first in a suite of high-performance electric two-wheelers that Zapp plans to bring to market. Zapp will offer a high-quality direct-to-customer experience known as DSDTC (drop-ship-direct-to-customer). Customers ordering the i300 online will have their bikes conveniently delivered to their home by authorised “Zappers,” who will provide at-home inspection, service and support throughout the vehicle ownership lifecycle. Zapp is a registered trademark of Zapp Electric Vehicles Limited in the United Kingdom and other countries.

 

Zoomcar Holdings, Inc. (NASDAQ:ZCAR) Founded in 2013 and headquartered in Bengaluru, India, Zoomcar is a marketplace for car sharing focused on emerging markets. The Zoomcar community connects Hosts with guests, who choose from a selection of cars for use at affordable prices, promoting sustainable, smart transportation solutions in growing markets.

 

New Stocks Added to the Biotech Directories:

CRISPR Therapeutics (Nasdaq:CRSP) Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that recently celebrated the historic approval of the first-ever CRISPR-based therapy and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY™ (exagamglogene autotemcel) was approved in some countries to treat eligible patients with either of those conditions. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom.

 

Becton, Dickinson and Company (NYSE:BDX) BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. 

 

New Stocks Added to the Retail Directories:

Aritzia Inc. (TSX: ATZ) is a design house with an innovative global platform. We are creators and purveyors of Everyday Luxury, home to an extensive portfolio of exclusive brands for every function and individual aesthetic. We're about good design, quality materials and timeless style — all with the wellbeing of our People and Planet in mind.

Founded in 1984 in Vancouver, Canada, we pride ourselves on creating immersive, highly personalized shopping experiences at aritzia.com and in our 115+ boutiques throughout North America — for everyone, everywhere.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

 

 

 

Biotech Stocks in Focus (NYSE American: $NNVC) (NYSE: $PFE) (NYSE: $GSK) (NASDAQ: $MRNA)

 

Biotech Stocks in Focus (NYSE American: $NNVC) (NYSE: $PFE) (NYSE: $GSK) (NASDAQ: $MRNA)

 

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

 

August 2, 2024 - Investorideas.com, a go-to investing platform covering biotech and nanotechnology issues a snapshot looking at news and developments in the antiviral market, featuring NanoViricides, Inc. (NYSE American: NNVC), a development stage company that is creating special purpose nanomaterials for antiviral therapy. 

 

From COVID to RSV and now Bird Flu, the global threat of viruses is only a headline away and there is a lot of profit for companies offering solutions. 

 

The Global Antiviral Drugs Market is estimated to reach USD 74.75 Bn by 2028, says Research and Markets and nanotech companies are aiming for a big piece of that pie.

 

Talking about nanotech’s future role in the antiviral market, a recent article in Nature says,  “Nanotechnology with precise control over the properties and structures of nanomaterials holds tremendous potential in the field of antiviral applications. The application of nanotechnology in the antiviral field, including the efficient delivery of antiviral drugs, the blocking of viral infections, and the activation of immune responses, offers new strategies and approaches, bringing renewed hope for infectious disease treatment and prevention.”

 

According to a recently released report from Zacks Small Cap Research, “NanoViricides (NYSE American: NNVC) Broad Spectrum Technology Represents Potential Paradigm Shift in Viral Therapy.”

 

Continued: “NanoViricides is a biopharmaceutical company developing anti-viral therapeutics based on its proprietary nanoviricide technology. A Phase 1 safety study of the company’s lead asset, NV-387, was recently completed and we anticipate results from the study being available in the second half of 2024. A Phase 2 clinical trial in Respiratory Syncytial Virus (RSV) is currently being planned. As opposed to currently available antiviral therapies in which each compound is only active against a unique type of virus, NanoViricides has disclosed preclinical results for NV-387 in multiple viral models that demonstrates the broad-spectrum action of the compound. These results could represent a new paradigm in viral therapy.”

 

Paid news dissemination on behalf of NanoViricides

 

Read this news, featuring NNVC in full at https://www.investorideas.com/news/2024/nanotech/08021Better-Solutions-for-Viruses.asp

 

On July 24^th NanoViricides issued a reminder on the strong safety and effectiveness against coronaviruses demonstrated by its lead clinical drug candidate NV-387.

 

"President Joe Biden has thankfully recovered from the bout of COVID caused by a new variant," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "This again brings into limelight the lack of strong drugs against COVID; a gap that NV-387 is expected to fulfill." 

 

From the news: There is clearly a need for a highly effective and preferably oral drug against COVID. COVID in the USA has become a biannual affair, with ever new, different variants leading each new wave. COVID continues to claim annually greater numbers of lives and hospitalizations than Influenza.

 

We believe it is important to bring to the attention of everyone how strong the activity of NV-387 in animal studies against coronaviruses has been, even compared with the most effective anti-coronavirus drug, namely, remdesivir (Veklury® Gilead).

 

We have studied a lethal lung infection in rats with a coronavirus that results in the same pathology but only milder than the delta variant, in humans as compared to COVID.

 

In one study, NV-387 intravenous injection (I.V.) treatment led to a substantial improvement in survival, of 180%, as compared to Remdesivir  (Pfizer Inc. NYSE:PFE), of only 50%.

 

Continued: We thereafter developed an oral formulation of NV-387 and studied its effect in comparison to the NV-387 I.V. treatment.

 

The results indicate that NV-387 oral drug is expected to be highly effective in treatment of COVID infections. The results also suggest that for hospitalized patients, NV-387 injectable form would be preferable over the oral form.

 

The focus throughout the pandemic has been primarily on antibodies and vaccines. Antibodies as drugs are now clearly evidenced to be not useful for a long enough period to provide major public health benefits. The limits of vaccines and vaccination campaigns both have also become clearly evident. In this scenario, Paxlovid™ (Pfizer Inc. NYSE:PFE),  remains the only oral drug available, in spite of its known weak clinical effectiveness, which is evidenced in clinical trials that showed that in otherwise healthy adults it was not shown to be better than placebo.

 

Additional drug development for COVID treatment is clearly a public health necessity. NV-387 is possibly the most advanced drug candidate that has demonstrated both strong activity and safety in a number of studies towards regulatory approvals.

 

NV-387 has undergone Phase I human clinical trial to evaluate the safety and tolerability in the form of two different oral formulations, namely, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies in India. There were no dropouts and there were no reported adverse events, indicating excellent safety and tolerability of NV-387 even at high dosage levels.

 

We have also found that NV-387 has a very wide antiviral spectrum, covering at least the following: Coronaviruses, RSV, Influenza, and Poxviruses (Smallpox/Mpox). This indicates that antiviral drug resistance against NV-387 would be highly unlikely.

 

Reporting on Pfizer’s (NYSE:PFE) Paxlovid™, Reuters recently noted, “A 15-day course of Pfizer's (PFE.N), opens new tab COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers.”

 

Continued: Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection.

 

Scientists and patients had hoped that Pfizer's two-drug oral treatment would ease symptoms of long COVID after anecdotal reports of patients who said Paxlovid helped them.

 

Continued: But the15-week, 155-participant study failed to show that a 15-day course helped more than a placebo in reducing fatigue, brain fog, shortness of breath, body aches, or gastrointestinal or cardiovascular symptoms. Trial participants, on average, had been sick more than 16 months before enrolling in the trial.

 

"We did not see a measurable difference based on patient reported outcomes in the six composite symptoms together," Stanford Medicine Professor, Dr. Upinder Singh said in an interview. "We didn't see a benefit in individual symptoms either."

 

The vaccine market is shifting after companies were making record profits during COVID, but there is still big money at play and new viruses to address. 

 

FiercePharma reported, “GSK (NYSE: GSK) reported sales of 1.24 billion euros ($1.53 billion) in the third and fourth quarter for its RSV shot Arexvy, which is for people ages 60 and older. Meanwhile, Sanofi and AZ-partnered pediatric shot Beyfortus generated 547 million euros ($592 million) in sales, a figure expected to double in 2024.”

 

Continued: “Industry experts who we’ve spoken to believe the global market opportunity for RSV vaccines is substantial, possibly reaching ($9 billion to $10 billion) and supporting attractive growth for leading companies,” Third Bridge’s Brown noted.

 

Zacks Equity Research looking at the biotech sector earlier this week, commented on Moderna, Inc. (NASDAQ:MRNA), once the darling of the COVID era, noting it is diversifying its pipeline. “Moderna recently obtained a significant boost with the FDA approval of RSV vaccine mResvia to prevent RSV-associated lower respiratory tract disease (RSV-LRTD) in older adults aged 60 years and above. The vaccine is scheduled for commercial launch during the 2024 fall season.

 

The company plans to launch several new marketed products over the next five years. With these potential launches, management aims to not only boost its revenues but also reduce dependence on Spikevax. As one of the first-ever COVID-19 vaccine makers, Moderna’s robust product sales boosted cash resources and enabled it to accelerate its pipeline development. The company is developing cytomegalovirus, cancer and influenza vaccines in late-stage studies.”

 

Vaccines are not the only answer to virus treatment, so  big pharma will be looking to innovate to capture market share and new opportunities.

 

NanoViricides, Inc. (NYSE American: NNVC) said in its most recent news, “We are now seeking collaborations with Pharma companies to bring this remarkable drug, NV-387, towards regulatory approvals for multiple antiviral indications.”

 

NanoViricides stated earlier in July, “We are living in a world with many viruses that threaten our health. The current model of developing a drug against each virus separately is expensive and untenable with the myriad of viruses affecting humans that are gaining major foothold.”

 

“NV-387 turns this drug development model on its head, with a single drug that would be effective against many of these viruses. It simplifies preparedness for pandemics. It reduces cost of development to a single drug instance.”

 

Research and find more biotech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

 

Research Nanotech stocks at Investorideas

https://www.investorideas.com/Nanotechnology/Stocks_List.asp

About Investorideas.com

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more.

 

Disclaimer/Disclosure: This news article featuring NanoViricides, Inc. (NYSE American: NNVC)  is a paid for news release creation and dissemination on Investorideas.com.  Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories

 

Nanotech Stocks- investing ideas in nanotechnology stocks,

Get more Nanotech news, articles, and stock directories

Breaking Mining Stock News: New Destiny Mining (TSXV: $NED.V) Drilling Update: First Hole Intersected Unmapped Historic Mine Workings at Treasure Mountain Silver Property, Hope BC; @NEDminingcorp

Breaking Mining Stock News: New Destiny Mining (TSXV: $NED.V) Drilling Update: First Hole Intersected Unmapped Historic Mine Workings at Treasure Mountain Silver Property, Hope BC; @NEDminingcorp

VANCOUVER, British Columbia - July 30, 2024 (Investorideas.com Newswire) New Destiny Mining Corp. (TSXV: NED), (the "Company" or "NED") provides the following update on its 2024 exploration program at the Treasure Mountain project, near Princeton, BC.

  Photo of Historic Railroad Mine Adit

The 2024 drilling program is underway at the Railroad copper-silver mineralized zone. Hole TMN24-01 was drilled under the 2019 trench, where an average grade of 0.64% copper and 116.0 ppm silver was channel sampled over 4.2 metres near the historic mine adit. This drill hole intersected unmapped historic mine workings, which are now recognized to be more extensive than originally estimated. It appears there was some excavation done on the Railroad zone in the historic mine. Hole TMN24-02 will be drilled from the same location at a steeper angle to try and intersect the zone below the historic workings.

Photo of drill on site No. 1 at Treasure Mountain Property

The Treasure Mountain property covers 10,819 hectares and is located 38 km west of the Copper Mountain mine at Princeton in southern BC. Targets on the property include critical minerals in porphyry copper-moly deposits, and gold-quartz vein and polymetallic silver-rich vein deposits.

 

Paid news dissemination on behalf of New Destiny Mining

 

Read this news, featuring NED in full at https://www.investorideas.com/news/2024/07301NED-Drilling-Update.asp

 

Map showing Treasure Mountain property and targets for 2024

Readers are cautioned that historical records referred to in this News Release have been examined but not verified by a Qualified Person. Further work is required to verify that historical records referred to in this News Release are accurate.

 

Dr. Mathew Ball, P.Geo., a Qualified Person as defined by NI 43-101 and consultant to the Company, approved the technical information contained in this News Release.

 

ON BEHALF OF THE BOARD OF DIRECTORS

"Al Beaton"

Director

604-488-3900

 

Investor Relations:
Lubica Parilakova
ir@NewDestinyMining.com

 

Forward Looking Information

This news release includes certain statements that constitute "forward-looking information" within the meaning of applicable securities law, including without limitation, the Company's information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the completion of the proposed transactions. Forward-looking statements address future events and conditions and are necessarily based upon a number of estimates and assumptions. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects" or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "estimates" or "intends", or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved), and variations of such words, and similar expressions are not statements of historical fact and may be forward-looking statements. Forward-looking statement are necessarily based upon several factors that, if untrue, could cause the actual results, performances or achievements of the Company to be materially different from future results, performances or achievements express or implied by such statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of gold and other metals, anticipated costs and the ability to achieve goals, and the Company will be able to obtain required licenses and permits. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks including that resource exploration and development is a speculative business; that environmental laws and regulations may become more onerous; that the Company may not be able to raise additional funds when necessary; fluctuating prices of metals; the possibility that future exploration, development or mining results will not be consistent with the Company's expectations; operating hazards and risks; and competition. There can be no assurance that economic resources will be discovered or developed. Accordingly, actual results may differ materially from those currently anticipated in such statements. Factors that could cause actual results to differ materially from those in forward looking statements include continued availability of capital and financing and general economic, market or business conditions, the loss of key directors, employees, advisors or consultants, equipment failures, litigation, competition, fees charged by service providers and failure of counterparties to perform their contractual obligations. Investors are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. The forward-looking statements included in this news release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation.

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

 

New Destiny Mining Corp. (TSXV: NED) is a featured mining stock on Investorideas.com

 

More info on NED at Investorideas.com Visit: https://www.investorideas.com/CO/NED/  

 

Disclaimer/Disclosure: New Destiny Mining Corp. (NED.V) is a paid featured mining stock on Investor Ideas. More info:Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact management and IR of each company directly regarding specific questions. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

 

Get more mining stock investor ideas- news, articles, and podcasts and stock directories

 

 

Canadian Miners to Watch; (TSX-V: $LBC.V) (TSX-V: $LEO.V) (TSX-V: $QCCU.V) (TSX: $HCU.V) (TSX: $MINE.V) (TSX: $ODV.V) (TSXV: $DFR.V) (TSX-V: $GGO.V)

Canadian Miners to Watch; (TSX-V: $LBC.V) (TSX-V: $LEO.V) (TSX-V: $QCCU.V) (TSX: $HCU.V) (TSX: $MINE.V) (TSX: $ODV.V) (TSXV: $DFR.V) (TSX-V: $GGO.V)

 

 

 

 

July 26, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Mining sector.  

 

The newest mining companies are listed on the TSX Venture Exchange and are involved in copper and gold mining.

 

Read this in full at https://www.investorideas.com/news/2024/main/07261Stocks.asp

 

Investor Ideas is always on the hunt for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector. 

 

New Stocks Added to the Mining Directories:

Libero Copper & Gold Corporation (TSX-V:LBC) is a mineral exploration company which is focussed on unlocking the value of the Mocoa copper-molybdenum porphyry deposit located in Putumayo, Colombia. Mocoa is being advanced by a highly disciplined and seasoned professional team with successful track records of discovery, resource development, and permitting in Colombia. Libero Copper prioritizes building strong relationships with the communities in which we operate and is dedicated to creating long-term value for our shareholders through responsible exploration to fuel the green energy future.

 

Lion Copper and Gold Corp (TSX-V:LEO) is a Canadian-based company advancing its flagship copper assets at Yerington, Nevada through an Option to Earn-in Agreement with Nuton LLC, a Rio Tinto Venture.

 

QC Copper and Gold Inc. (TSX-V:QCCU) is focused on advancing its past-producing Opemiska Copper Mine Complex in the Chapais-Chibougamau region of Quebec. 

 

Horizon Copper Corp (TSX:HCU.V) is a premier copper company holding a portfolio of unparalleled copper assets including a 30% interest in the copper-gold Hod Maden project, exposure to the Oyu Tolgoi copper mine through a 25% equity ownership in Entrée Resources Ltd., and a 1.66% net profits interest on the Antamina copper mine. Horizon plans to actively grow its portfolio of assets with a focus on copper projects.

 

Inomin Mines Inc (TSX:MINE.V) is focused on the identification, acquisition, and exploration of mineral properties with strong potential to host significant resources, especially critical minerals, as well as gold and silver projects.

Osisko Development (TSX:ODV.V) is a North American gold development company focused on past-producing mining camps located in mining friendly jurisdictions with district scale potential. The Company's objective is to become an intermediate gold producer by advancing its 100%-owned Cariboo Gold Project, located in central B.C., Canada, the Tintic Project in the historic East Tintic mining district in Utah, U.S.A., and the San Antonio Gold Project in Sonora, Mexico. In addition to considerable brownfield exploration potential of these properties, that benefit from significant historical mining data, existing infrastructure and access to skilled labour, the Company's project pipeline is complemented by other prospective exploration properties. The Company's strategy is to develop attractive, long-life, socially and environmentally sustainable mining assets, while minimizing exposure to development risk and growing mineral resources.

 

DFR Gold Inc (TSXV:DFR) is a TSX Venture Exchange listed exploration and mine development company focused on gold in West Africa and holds interests in a portfolio of West African gold exploration projects including the Gurara project in Nigeria and the highly prospective Cascades gold exploration project in Burkina Faso. DFR Gold also owns the Beravina project, an advanced high grade hard rock zircon exploration prospect located in the western Madagascar.

 

Galleon Gold (TSX-V:GGO) is an advanced exploration and development company focused on the West Cache Gold Project in Timmins, Ontario. The West Cache Gold Project is located 7 km northeast of Pan American Silver's Timmins West Mine and 14 km southwest of Newmont's Hollinger Mine. A 2022 Preliminary Economic Assessment (PEA) for the Project demonstrates strong economics. The Company is in the process of planning and permitting for an 86,500-tonne underground bulk sample.

 

 

For the avid Mining Stock Investors – Check out our free comprehensive directory of Mining Stocks Mining Stocks Directory

 

 

 

Stay up to date on current mining sector news at https://www.investorideas.com/Gold_Stocks/ and Get News Alerts on Mining Stocks

 

 

Check out the Exploring Mining podcast by Investor Ideas for the latest mining stock news and insightful interviews with top industry experts. We're proud to have been recognized as number 1 in the top 30 Mining Podcasts to listen to in 2024 by Feedspot based on a review of thousands of podcasts on the web and ranked by traffic, social media followers & freshness. Host Cali Van Zant interviews CEO's and analysts to give you insight into the sector. Stay ahead of the game with Exploring Mining.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X)  https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411